Drugmakers are turning to vitamins for a shot of consumer health growth, and a host of supplement makers are prime targets. But with consumer product companies vying for the same buyouts, prices could be steep. Report
Drugmakers are turning to vitamins for a shot of consumer health growth, and a host of supplement makers are prime targets. But with consumer product companies vying for the same buyouts, prices could be steep. Report